India's Serum Institute asks government for $403 million to boost AstraZeneca vaccine output

April 7, 2021 9:33 AM EDT

FILE PHOTO: A health official draws a dose of AstraZeneca's COVID-19 vaccine manufactured by the Serum Institute of India, at Infectious Diseases Hospital in Colombo, Sri Lanka January 29, 2021. REUTERS/Dinuka Liyanawatte


Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

NEW DELHI (Reuters) - The Serum Institute of India, the world's biggest vaccine manufacturer, has asked the government for a grant of 30 billion rupees ($402.97 million) to increase its capacity to make AstraZeneca's COVID-19 vaccine.

It is seeking the money to ramp up monthly production to more than 100 million doses by the end of May, the government said in a statement on Wednesday, noting output was currently around 65-70 million doses a month.

The company is making vaccine doses for dozens of mainly poorer countries, though it has supplied Britain, Canada and Saudi Arabia due to AstraZeneca production issues elsewhere.

About 90% of the 86 million doses India has administered since mid-January have come from the institute, with the rest accounted for by a domestic vaccine developed by Bharat Biotech, which is also struggling to boost output.

Some Indian states have complained of a vaccine shortage even though immunisations are currently limited to front-line workers and people aged over 45, or 400 million of India's 1.35 billion people.

($1 = 74.4480 Indian rupees)

(Reporting by Krishna N. Das; Editing by Kirsten Donovan)



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Reuters